Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Diastolic Pressure Could Play a Dirty Trick on Patients Treated for Hypertension

Having too low diastolic pressure could be linked to an increase in cardiovascular events (J-shape phenomenon). However, current guidelines suggest a target blood pressure under 130/80 mmHg with no lower limit for diastolic pressure.

Las nuevas guías Europeas de Hipertensión contrastan con las Americanas

This paper, recently published in JAMA, sought to evaluate the J-shape phenomenon of diastolic pressure in treated patients who reached a target systolic pressure under 130 mmHg—as guidelines recommend.

The cohort of patients was divided into the following intervals of diastolic pressure: less than 60 mmHg, between 60 and 70 mmHg, between 70 and 80 mmHg, and more than 80 mmHg.

The study’s primary endpoint was a composite of all-cause mortality, myocardial infarction, and stroke. The secondary endpoint included death due to cardiovascular causes, infarction, and non-fatal stroke.

The analysis included 7515 patients with a mean age of 65.6 years.

The lower risk for events was observed in patients with a diastolic pressure between 70 and 80 mmHg.


Read also: What to Do with Blood Pressure Levels Between 130/80 and 139/89 mmHg.


A mean diastolic pressure under 60 mmHg was linked to a significant increase in the primary endpoint risk (hazard ratio [HR]: 1.46; 95% confidence interval [CI]: 1.13-1.90; p = 0.004).

In relation to the composite, it was even more significant: death for cardiovascular causes (HR: 1.74; 95% CI: 1.26-2.41; p = 0.001), non-fatal stroke (HR: 1.73; 95% CI: 1.15-2.59; p = 0.008), and non-fatal stroke (HR 2.67; 95% CI: 1.26-5.63; p = 0.01).

Conclusion

This cohort study showed that a too low diastolic pressure (under 60 mmHg) was associated with an increase in cardiovascular events in treated patients who had reached a target systolic pressure of 130 mmHg or less.

The finding of an ideal systolic pressure between 70 and 80 mmH should be studied further.

Original Title: Evaluation of Optimal Diastolic Blood Pressure Range Among Adults With Treated Systolic Blood Pressure Less Than 130 mm Hg.

Reference: Jingen Li et al. JAMA Network Open. 2021;4(2):e2037554. doi:10.1001/jamanetworkopen.2020.37554.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...

DOUBLE-CHOICE: Lower Pacemaker Implantation Rates with ACURATE neo2 Compared with Evolut in Patients Undergoing TAVI

The DOUBLE-CHOICE trial is a multicenter, randomized, controlled study conducted in Germany to evaluate the performance of next-generation transcatheter heart valves and different anesthesia...

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...